Organization

KEYSTONE LABORATORIES, INC.

According to 2025 Medicare claims, KEYSTONE LABORATORIES, INC. (NPI: 1104258995) practices clinical laboratory (billing independently) in the Asheville, NC market, with the plurality of this provider's patient population coming from Henderson, NC. This provider's primary affiliated billing organization is KEYSTONE LABORATORIES, INC. (NPI: 1104258995; TIN: 521544806) and primary practice location at 28801-4103.

The organization's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,047 traditional Medicare patients, billed 3,634 HCPCS/CPT codes, and received $363,979 in Medicare payments. The top billing code was G0483 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $437,040 and ending at $363,979. Concurrently, this provider has fewer than 5 years of reported Part D prescription costs data, so a reliable trend cannot be assigned. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$567K$1.1M2015 Medicare payment: $437,040 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $339,833 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $404,677 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $309,998 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $425,432 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,023,255 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,134,728 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $741,950 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $439,095 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $363,979 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201592617,516$437,040
20161,4283,230$339,833
20171,2783,541$404,677
20181,0943,061$309,998
20191,5854,096$425,432
20202,92612,664$1,023,255
20212,48020,197$1,134,728
20221,85011,458$741,950
20231,1674,147$439,095
20241,0473,634$363,979

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

No connected Part D records

No connected Part D records

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
G0483Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms459755$242
G0482Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms240342$195
G0481Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms149221$153
80307Testing for presence of drug, by chemistry analyzers666981$61
87086Bacterial colony count, urine151179$8

Top 5 Part D drugs in 2024

By total drug costs.

No connected Part D drug-level records for 2024.

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for KEYSTONE LABORATORIES, INC.?

Tedicare shows public-source Medicare data for KEYSTONE LABORATORIES, INC. (NPI 1104258995), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does KEYSTONE LABORATORIES, INC. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to KEYSTONE LABORATORIES, INC.?

KEYSTONE LABORATORIES, INC. is linked to KEYSTONE LABORATORIES, INC. (billing NPI 1104258995) in the available physician profile data.

Does KEYSTONE LABORATORIES, INC. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.